Mesenchymal Stem Cells: A Therapeutic Approach to POAG
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
G2006043
Acknowledgement
Summary
Glaucomas are a group of eye diseases that lead to a gradual loss of vision that may result in blindness. There is still no cure for glaucoma, and current treatments consist of methods aimed at restoring the intraocular pressure levels. Argon laser trabeculoplasty has provided an effective therapy for glaucoma. However, the efficiency of laser therapy is limited to a short period of time, and repetitive procedures are usually required. One possible explanation for this limited efficiency is aging. As we get old, the regenerative potential of the tissues is diminished due to the lost and aging of progenitor cells. Results from the laboratory suggest an accumulation of aged cells in the drainage canal of the glaucomatous eye. The accumulation of aged nonfunctional cells may be responsible the limited regenerative potential following laser therapy. Dr. Gonzalez’s hypothesis is that transplantation of young progenitor cells following laser therapy will replace the laser-damaged cells; that these transplanted progenitor cells will repopulate the aged-drainage canal; and that this repopulation will recover the drainage canal functionality. He proposes to explore the use of adult mesenchymal stem cells from the bone marrow as a potential cellular replacement therapeutic strategy combined with laser therapy.
Related Grants
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine